Suppr超能文献

长链非编码 RNA TUG1 通过充当 miR-1-3p 的 ceRNA 促进肝癌发生中的细胞增殖。

LncRNA TUG1 functions as a ceRNA for miR-1-3p to promote cell proliferation in hepatic carcinogenesis.

机构信息

The Affiliated Hospital of the Medical School of Ningbo University, Ningbo, China.

出版信息

J Clin Lab Anal. 2022 May;36(5):e24415. doi: 10.1002/jcla.24415. Epub 2022 Apr 14.

Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is characterised by high malignancy, metastasis and recurrence, but the specific mechanism that drives these outcomes is unclear. Recent studies have shown that long noncoding RNAs (lncRNAs) can regulate the proliferation and apoptosis of hepatic cells.

METHODS

We searched for lncRNAs and microRNAs (miRNAs), which can regulate IGF1 expression, through a bioinformatics website, and predicted that lncRNA taurine-upregulated gene 1 (TUG1) would have multiple targets for miR-1-3p binding, meaning that lncRNA TUG1 played an adsorption role. A double luciferase assay was used to verify the targeting relationship between lncRNA TUG1 and miR-1-3p. Western blotting and qPCR were used to verify the targeting relationship between miR-1-3p and IGF1, and qPCR was used to verify the regulatory relationship between the lncRNA TUG1-miR-1-3p-IGF1 axis. CCK-8 was used to detect the growth activity of miRNA-transfected L-O2 cells, and flow cytometry was used to detect cell cycle changes and apoptosis.

RESULT

The proliferation cycle of L-O2 cells transfected with miR-1-3p mimics was significantly slowed. Flow cytometry showed that the proliferation of L-O2 cells was slowed, and the apoptosis rate was increased. In contrast, when L-O2 cells were transfected with miR-1-3p inhibitor, the expression of IGF1 was significantly upregulated, and the cell proliferation cycle was significantly accelerated. Flow cytometry showed that the cell proliferation rate was accelerated, and the apoptosis rate was reduced.

CONCLUSION

LncRNA TUG1 can adsorb miR-1-3p as a competitive endogenous RNA (ceRNA) to promote the expression of IGF1 and promote cell proliferation in hepatic carcinogenesis.

摘要

背景

肝细胞癌 (HCC) 的特点是恶性程度高、转移和复发,但其驱动这些结果的具体机制尚不清楚。最近的研究表明,长链非编码 RNA (lncRNA) 可以调节肝实质细胞的增殖和凋亡。

方法

我们通过生物信息学网站搜索可调节 IGF1 表达的 lncRNA 和 microRNA (miRNA),并预测 lncRNA 牛磺酸上调基因 1 (TUG1) 将有多个 miR-1-3p 结合的靶点,这意味着 lncRNA TUG1 发挥吸附作用。双荧光素酶报告基因实验验证 lncRNA TUG1 与 miR-1-3p 的靶向关系。Western blot 和 qPCR 验证 miR-1-3p 与 IGF1 的靶向关系,qPCR 验证 lncRNA TUG1-miR-1-3p-IGF1 轴的调控关系。CCK-8 检测转染 miRNA 的 L-O2 细胞的生长活性,流式细胞术检测细胞周期变化和凋亡。

结果

转染 miR-1-3p 模拟物的 L-O2 细胞的增殖周期明显减慢。流式细胞术显示 L-O2 细胞的增殖减慢,凋亡率增加。相反,当 L-O2 细胞转染 miR-1-3p 抑制剂时,IGF1 的表达明显上调,细胞增殖周期明显加快。流式细胞术显示细胞增殖速度加快,凋亡率降低。

结论

lncRNA TUG1 可作为竞争性内源性 RNA (ceRNA) 吸附 miR-1-3p,促进 IGF1 的表达,促进肝癌发生中的细胞增殖。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/652f/9102766/b8d776437182/JCLA-36-e24415-g004.jpg

相似文献

1
LncRNA TUG1 functions as a ceRNA for miR-1-3p to promote cell proliferation in hepatic carcinogenesis.
J Clin Lab Anal. 2022 May;36(5):e24415. doi: 10.1002/jcla.24415. Epub 2022 Apr 14.
2
LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in osteosarcoma by regulating miR-212-3p/FOXA1 axis.
Biomed Pharmacother. 2018 Jan;97:1645-1653. doi: 10.1016/j.biopha.2017.12.004. Epub 2017 Dec 8.
5
The miRNA mir-582-3p suppresses ovarian cancer progression by targeting AKT/MTOR signaling lncRNA TUG1.
Bioengineered. 2021 Dec;12(2):10771-10781. doi: 10.1080/21655979.2021.2003662.
6
Knockdown of TUG1 by shRNA inhibited renal cell carcinoma formation by miR-299-3p/VEGF axis in vitro and in vivo.
Eur J Pharmacol. 2019 Oct 5;860:172536. doi: 10.1016/j.ejphar.2019.172536. Epub 2019 Jul 13.
8
LncRNA TUG1 promotes Ewing's sarcoma cell proliferation, migration, and invasion via the miR-199a-3p-MSI2 signaling pathway.
Neoplasma. 2021 May;68(3):590-601. doi: 10.4149/neo_2021_201110N1198. Epub 2021 Mar 30.
9
LncRNA TUG1 contributes to ESCC progression via regulating miR-148a-3p/MCL-1/Wnt/β-catenin axis in vitro.
Thorac Cancer. 2020 Jan;11(1):82-94. doi: 10.1111/1759-7714.13236. Epub 2019 Nov 19.
10
LncRNA TUG1 exhibits pro-fibrosis activity in hypertrophic scar through TAK1/YAP/TAZ pathway via miR-27b-3p.
Mol Cell Biochem. 2021 Aug;476(8):3009-3020. doi: 10.1007/s11010-021-04142-0. Epub 2021 Mar 31.

引用本文的文献

3
Plasma miR-1-3p levels predict severity in hospitalized COVID-19 patients.
Br J Pharmacol. 2025 Jan;182(2):451-467. doi: 10.1111/bph.17392. Epub 2024 Nov 21.
4
LncRNA TUG1 and its Molecular Mechanisms in Human Cancer.
Curr Mol Med. 2025;25(6):686-696. doi: 10.2174/0115665240298173240427042624.
5
The role of competing endogenous RNA network in the development of hepatocellular carcinoma: potential therapeutic targets.
Front Cell Dev Biol. 2024 Jan 31;12:1341999. doi: 10.3389/fcell.2024.1341999. eCollection 2024.
6
A serum panel of three microRNAs may serve as possible biomarkers for kidney renal clear cell carcinoma.
Cancer Cell Int. 2024 Jan 8;24(1):18. doi: 10.1186/s12935-023-03187-z.
7
The important role of miR-1-3p in cancers.
J Transl Med. 2023 Oct 31;21(1):769. doi: 10.1186/s12967-023-04649-8.
8
overexpression leads to lenvatinib resistance in hepatocellular carcinoma.
J Gastrointest Oncol. 2023 Jun 30;14(3):1412-1433. doi: 10.21037/jgo-23-277.
9
analysis to identify novel ceRNA regulatory axes associated with gallbladder cancer.
Front Genet. 2023 Feb 16;14:1107614. doi: 10.3389/fgene.2023.1107614. eCollection 2023.

本文引用的文献

2
-Mediated Regulation of mA-Modified by mA Reader IGF2BP3 Drives ccRCC Progression.
Cancer Res. 2021 Feb 15;81(4):923-934. doi: 10.1158/0008-5472.CAN-20-1619. Epub 2020 Dec 8.
3
Ultraconserved element uc.333 increases insulin sensitivity by binding to miR-223.
Aging (Albany NY). 2020 Apr 17;12(8):6667-6679. doi: 10.18632/aging.103020.
6
MiR-1-3p suppresses cell proliferation and invasion and targets STC2 in gastric cancer.
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8870-8877. doi: 10.26355/eurrev_201910_19282.
8
miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9.
Onco Targets Ther. 2019 Mar 22;12:2149-2157. doi: 10.2147/OTT.S197326. eCollection 2019.
9
MiR-1-3p Inhibits Lung Adenocarcinoma Cell Tumorigenesis via Targeting Protein Regulator of Cytokinesis 1.
Front Oncol. 2019 Mar 1;9:120. doi: 10.3389/fonc.2019.00120. eCollection 2019.
10
Cancer statistics, 2019.
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验